Product Reports Resources Pricing Login Book a demo

Synthego

Biotech & Life Sciences · Menlo Park, United States · Founded 2012

Provider of synthetic RNA solutions for CRISPR genome engineering MoreLess

Synthego is a biotechnology company that operates in the field of genetic engineering. It specializes in providing synthetic RNA (ribonucleic acid) and gene editing tools. RNA is a molecule that plays a crucial role in coding, decoding, regulation, and expression of genes. In simpler terms, Synthego's products help scientists to modify genes, which can lead to breakthroughs in treating diseases or improving crop yields.

The company serves a diverse range of clients, including research institutions, pharmaceutical companies, and biotech startups. These clients use Synthego's products for various purposes, such as drug discovery, disease modeling, and genetic research.

Synthego operates in the rapidly growing market of genetic engineering and synthetic biology. The demand for its products is driven by the increasing investment in genetic research and the growing application of gene editing in various fields.

The company's business model revolves around the production and sale of synthetic RNA and gene editing tools. It generates revenue by selling these products directly to its clients. Additionally, Synthego also offers a platform for genetic engineering, which provides users with access to advanced gene editing capabilities.

In conclusion, Synthego is a key player in the genetic engineering market, providing essential tools and services for gene editing and research. Its innovative products and platform have positioned it well to capitalize on the growing demand for genetic engineering solutions.

Keywords: Biotechnology, Genetic Engineering, Synthetic RNA, Gene Editing Tools, Research Institutions, Pharmaceutical Companies, Biotech Startups, Drug Discovery, Disease Modeling, Genetic Research.

Company overview

Synthego company information

The essential company record, classifications and operating signals in one place.

Status
Acquired
Founded
2012
Headquarters
Menlo Park, United States
Employees
170
Open positions
3
Dealroom signal
69.5
client focusb2csub industryBioTechnologybusiness modelManufacturingsectorIndustrial AutomationsectorInnovation ManagementindustryHealthsectorBiotechnologysectorDNAsectorGenetics and genomicssectorSynthetic BiologysectorCrisprsectorGenome EngineeringsectorRumoured $1BsectorBiotech and Pharma

Valuation & funding

Synthego funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
BUYOUTOther financing Jul 2025 $0 Perceptive Advisors
SERIES EOther financing Feb 2022 $200M $800M RA Capital Management · Declaration Partners · Moore Strategic Ventures · Chimera
SERIES DOther financing Aug 2020 $100M $550M Menlo Ventures · Founders Fund · RA Capital Management · Intel Capital
SERIES COther financing Oct 2018 $110M $440M Founders Fund · Menlo Ventures · 8VC
EARLY VCOther financing Oct 2017 Intel Capital
SERIES BOther financing Jan 2017 WI Harper Group · Founders Fund · Arab Angel Fund · SciFi VC
EARLY VCOther financing Aug 2016 Undisclosed
SERIES AOther financing Jul 2013 Menlo Ventures · WI Harper Group · Founders Fund
DEBTDebt Aug 2012 Undisclosed
Showing 9 recorded eventsUnlock the complete deal history →

Growth signals

Synthego website traffic

Latest recorded traffic for Synthego is 120K monthly website visits, up 34.8% over the last three months. Synthego's team grew 3% over the past year.

Latest monthly visits120K 3-month web change+34.8% 1-year team growth+3%
Monthly website visits123 observations · Apr 2016–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Synthego compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
EGenesisA gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues, and cells to address the global organ crisis Cambridge, United States Operational 154 $470M $764M
Editas MedicineUnlocking the promise of genome editing to deliver life-changing medicines Cambridge, United States Operational
Pioneer BiolabsB2B biomanufacturing company leveraging its proprietary genomic screening platform to engineer and optimize microbial cells for protein production Provo, United States Operational
Emendo BiotherapeuticsDevelops next-generation gene editing using synthetic biology to address untreatable diseases New York City, United States Operational
Intellia TherapeuticsA leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases Cambridge, United States Operational
Caribou BiosciencesBiotechnology company focused on genome engineering and developing technology-based solutions for cells Berkeley, United States Operational
HelixThe leading population genomics company working at the intersection of clinical care, research, and genomics San Mateo, United States Operational
Affini-T TherapeuticsBiotechnology company developing T-cell therapies for patients suffering from cancer Boston, United States Operational
Showing 8 of the closest matchesCompare every metric →

Talent graph

Synthego's talent

Book a demo to see the people
Team profiled 37 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

21 investors on Synthego's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 11 investors entered at this stage
Menlo Ventures
WI Harper Group
Founders Fund
8VC
Arab Angel Fund
SciFi VC
OS Fund
Alexandria Venture Investments
ZhenFund
Jerry Yang
Intel Capital
Series B+ 10 investors entered at this stage
RA Capital Management
Wellington Management
Perceptive Advisors
Declaration Partners
Moore Strategic Ventures
Chimera
SoftBank
Logos Capital
Gigafund
Laurion Capital Management

Global footprint

Where Synthego has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States95.6%
🇦🇺 Australia1.5%
🇩🇪 Germany0.7%
🇵🇭 Philippines0.7%
🇳🇱 Netherlands0.7%
Top 5 of 6 shown

In the news

Latest news about Synthego

Recent press, funding announcements, and product moves mentioning Synthego — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Synthego

An AI-synthesized read of the highest-engagement posts about Synthego on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Synthego’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.